富平滑肌肾细胞癌的临床、肿瘤学、遗传与病理特征
本文回顾性分析2008年至2025年单中心26例富平滑肌肾细胞癌(smrRCC)患者,中位初诊手术年龄59.5岁,73.1%为男性,88.5%为双侧多灶性肾 masses。共行48次肾手术,切除216个肿瘤,79.2%为smrRCC组织学;1例pT3 grade 3患者出现转移,8例(30.7%)检出意义未明的胚系ASXL1变异。
要点
- smrRCC多见于黑人/非裔美国人,常表现为双侧多灶性病变,需多次肾手术。
- 同一患者病理可同时存在smrRCC与其他组织学类型,病理分级和分期可能影响转移潜能。
- 胚系ASXL1变异可能增加smrRCC风险,但均为意义未明变异。
核心结论
- smrRCC常表现为双侧多灶性疾病,患者需多次肾手术,病理分级和分期可能影响肿瘤学行为及转移潜能。
- 胚系ASXL1变异可能增加smrRCC风险,但本队列未发现主要遗传学改变。
研究设计与样本
- 单中心回顾性病历分析,纳入2008年1月至2025年4月治疗的26例smrRCC患者。
- 收集临床、手术、病理及遗传学数据进行分析。
主要发现
- 26例患者中,初诊肾手术中位年龄59.5岁(范围51.5-65.3),男性19例(73.1%),黑人/非裔美国人19例(73.1%)。
- 影像学双侧多灶性肾 masses 23例(88.5%),共行48次肾手术,每次手术切除肿瘤中位数4个(范围2-6)。
- 34次(70.8%)手术仅报告smrRCC为主型肿瘤,共切除216个肿瘤,其中171个(79.2%)为smrRCC组织学。
- 1例初诊smrRCC pT3肿瘤(ISUP/Furman分级3级)患者发生转移性疾病。
- 8例(30.7%)患者检出意义未明的胚系ASXL1变异。
临床怎么用
- 对双侧多灶性肾 masses 患者应警惕smrRCC可能,并评估多次肾手术的必要性。
- 病理报告需注意同一患者可能合并smrRCC与其他组织学类型,应结合分级和分期评估转移风险。
- 可考虑对smrRCC患者进行遗传咨询和胚系ASXL1变异检测,但意义未明变异的临床价值需进一步研究。
局限性
- 单中心回顾性研究,样本量较小(26例),可能存在选择偏倚。
- 胚系ASXL1变异均为意义未明变异,其与smrRCC风险的因果关系尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To present our institutional experience with Smooth Muscle-Rich Renal Cell Carcinoma (smrRCC), focusing on clinical presentation, surgical management, oncologic outcomes, and genetic features. MATERIAL AND METHODS: A retrospective chart review of patients with smrRCC treated at our institution between January 2008 and April 2025 was performed. Clinical, surgical, pathological, and genetic data were collected and analyzed. RESULTS: A total of 26 patients with smrRCC were identified; the median age at initial renal surgery was 59.5 [51.5-65.3] years. The cohort included 19 (73.1%) males, 19 (73.1%) patients identified as Black/African American, and radiologically bilateral multifocal (BMF) renal masses were observed in 23 (88.5%) patients. Patients underwent 48 renal surgeries, 4 [2-6] tumors were removed per surgery, and 34 (70.8%) surgeries reported smrRCC predominant tumors only. In total, 216 tumors were resected, with 171 (79.2%) tumors demonstrating smrRCC histology. One patient with an initial smrRCC pT3 tumor (ISUP/ Furman grade 3) developed metastatic disease. We observed germline ASXL1 variants of uncertain significance in 8 (30.7%) patients. CONCLUSION: smrRCC appears to frequently affect Black/African American individuals, although no predominant genetic alterations were identified in our cohort, smrRCC often presents with BMF disease, and patients require multiple renal surgeries. Genetic evaluations offer an intriguing possibility that germline ASXL1 gene variants might increase the risk of this tumor type. Pathology reports may reveal both smrRCC and other histologies within the same patient. Our findings suggest that pathological grade and stage may influence oncologic behavior and metastatic potential of smrRCC.
引用
- Blachman-Braun R, Patel MH, Millan B, et al. Unraveling Smooth Muscle-rich Renal Cell Carcinoma: Clinical, Oncological, Genetic, and Pathological Insights. Urology. 2025. PMID: 41260417. doi:10.1016/j.urology.2025.11.234
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。